Första kliniska data för Remygen Diamyd presenterade under gårdagen data från en fas I/II-studie (n=...
SmartCraft levererade ytterligare ett starkt kvartal med hög tillväxt.
Redeye updates its estimates and base case following Fantasma Games’ Q1 report, which showed high gr...
Redeye provides its comment on Ultimovacs’ Q1 2023 report, which featured no surprises.
Redeye updates its estimates following FlexQube’s Q1 report, where sales was significantly lower tha...
Redeye provides its comment on Sprint Bioscience’s Q1 2023 report, and we judge that the company nee...
Redeye updates on W5 Solutions after its Q1-results which saw somewhat higher revenue and EBITDA tha...
Redeye saw a Q1 report that was slightly weaker than expected but not a material deviation.
Redeye leaves its comments on Acarix following its Q1 2023 report, which did not contain any major s...
Redeye states that Truecaller delivered revenues below estimates, but that adjusted EBIDTA beat cons...
The main points is that Ascelia reminds investors that Last Patient Last Visit (LPLV) was completed ...
Redeye comments on Tessin’s Q1 results, which showed solid growth despite a significant cost reducti...
In 2022, Brain+ had a successful commercial introduction of its CST-Therapist Companion dementia pro...
Weaker EBIT partly due to lower than expected Öyfjellet contribution Project portfolio of ~24.
Redeye comments on Mestro’s Q1 2023 report and on the announced indicative public takeover offer in ...
Raketech just released super solid set of Q1 numbers, and a better than expected start to the second...
